Coronary Artery Bypass Graft Surgery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Coronary Artery Bypass Graft Surgery Pipeline Products Market Report Overview

Coronary artery bypass graft surgery devices are used in the surgery to improve blood flow to the obstructed coronary artery. Surgeons use these devices to treat people who have severe coronary heart disease. The Coronary Artery Bypass Graft Surgery pipeline market research report provides comprehensive information about the Coronary Artery Bypass Graft Surgery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Coronary Artery Bypass Graft Surgery Pipeline Products Market Segmentation by Territories

The key territories with products in the pipeline are the US, Europe, Israel, and Canada. As of February 2023, the US has the highest number of products in the pipeline out of them all.

Coronary Artery Bypass Graft Surgery Pipeline Products Market Analysis, by Territories, 2023 (%)

Coronary Artery Bypass Graft Surgery Pipeline Products Market Analysis, by Territories, 2023 (%)

For more territory insights into the Coronary Artery Bypass Graft Surgery pipeline products market, download a free report sample

Coronary Artery Bypass Graft Surgery Pipeline Products Market Segmentation by Regulatory Paths

The key regulatory paths followed by the Coronary Artery Bypass Graft Surgery pipeline products market are PMA, CE, 510(k), and MDL. Most of the products follow the PMA pathway to enter the market.

Coronary Artery Bypass Graft Surgery Pipeline Products Market Analysis, by Regulatory Paths, 2023 (%)

Coronary Artery Bypass Graft Surgery Pipeline Products Market Analysis, by Regulatory Paths, 2023 (%)

For more Coronary Artery Bypass Graft Surgery pipeline products regulatory path insights, download a free report sample

Coronary Artery Bypass Graft Surgery Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Coronary Artery Bypass Graft Surgery pipeline products market are AdvanSource Biomaterials Corporation, ArtiFex Medical GmbH, Axcelon Biopolymers Corp, CardioPolymers Inc, Cardious Inc, Centre Hospitalier Universitaire de Nice, Coromedic Ltd., Cytograft Tissue Engineering Inc (Inactive), Elana bv, and enVVeno Medical Corp.

AdvanSource Biomaterials Corporation: Headquartered in Wilmington, Massachusetts, USA, AdvanSource is a polymer materials company that develops polymer materials used in the design and development of medical devices. AdvanSource’s services include customized materials, product extensions, custom solutions, and project management. The company has a presence in the US, Canada, China, India, and Egypt.

Axcelon Biopolymers Corp: It is an innovative biomaterials company focused on leveraging its unique bacterial nanocellulose platform technology to develop high value products for wound care, medical devices, tissue engineering, and industrial applications. The company has its presence in London, and Canada.

Cardious Inc: Headquartered in Northfield, Minnesota, USA, Cardious is a medical device company that offers valve bypass graft systems. The company offers minimally invasive heart valve therapies. Cardious’ proprietary product aortic valve bypass graft system is a minimally invasive alternative to traditional aortic valve replacement therapy. The company’s valve bypass graft systems are used as beating heart alternative to traditional aortic valve replacement therapy. It caters to cardiac surgeons, hospitals, and medical centers. The company markets its products across the US.

For more company insights into the Coronary Artery Bypass Graft Surgery pipeline products market, download a free report sample

Coronary Artery Bypass Graft Surgery Pipeline Products Market Report Overview

Key Territories The US, Europe, Israel, and Canada
Key Regulatory Paths PMA, CE, 510(k), and MDL
Leading Companies AdvanSource Biomaterials Corporation, ArtiFex Medical GmbH, Axcelon Biopolymers Corp, CardioPolymers Inc, Cardious Inc, Centre Hospitalier Universitaire de Nice, Coromedic Ltd., Cytograft Tissue Engineering Inc (Inactive), Elana bv, and enVVeno Medical Corp

Scope

This report provides an in-depth analysis of:

  • Coronary artery bypass graft surgery devices under development
  • Details of major pipeline products which includes product description, licensing and collaboration details, and other developmental activities
  • Major players involved in the development of coronary artery bypass graft surgery devices and lists all their pipeline projects
  • Pipeline products based on various stages of development ranging from early development to approved/issued stage
  • Key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage
  • Identify and understand important and diverse types of Coronary Artery Bypass Graft Surgery under development
  • Develop market-entry and market-expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date

AdvanSource Biomaterials Corporation
ArtiFex Medical GmbH
Axcelon Biopolymers Corp
CardioPolymers Inc
Cardious Inc
Centre Hospitalier Universitaire de Nice
Coromedic Ltd.
Cytograft Tissue Engineering Inc (Inactive)
Elana bv
enVVeno Medical Corp
Graft-Loc Inc.
H. Lee Moffitt Cancer Center & Research Institute Inc
iiTech BV
McGill University
Medical 21 Inc
Myocardial Assist Systems and Technology LLC
Neograft Technologies Inc
PetVivo Holdings Inc
Prekubator TTO
RegenMedTX LLC
SeamVad Ltd.
Surg Solutions SL
Synovis Micro Companies Alliance Inc
Thoratec LLC
Tissue Regeneration Technologies LLC
University College London
University of Arizona
University of California Davis
University of California Los Angeles
Xeltis AG

Table of Contents

  • 1 Table of Contents

    • 1.1 List of Tables
    • 1.2 List of Figures

  • 2 Introduction

    • 2.1 Coronary Artery Bypass Graft Surgery Overview

  • 3 Products under Development

    • 3.1 Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development
    • 3.2 Coronary Artery Bypass Graft Surgery – Pipeline Products by Territory
    • 3.3 Coronary Artery Bypass Graft Surgery – Pipeline Products by Regulatory Path
    • 3.4 Coronary Artery Bypass Graft Surgery – Pipeline Products by Estimated Approval Date
    • 3.5 Coronary Artery Bypass Graft Surgery – Ongoing Clinical Trials

  • 4 Coronary Artery Bypass Graft Surgery – Pipeline Products under Development by Companies

    • 4.1 Coronary Artery Bypass Graft Surgery Companies – Pipeline Products by Stage of Development
    • 4.2 Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development

  • 5 Coronary Artery Bypass Graft Surgery Companies and Product Overview

    • 5.1 AdvanSource Biomaterials Corporation Company Overview

      • 5.1.1 AdvanSource Biomaterials Corporation Pipeline Products & Ongoing Clinical Trials Overview

    • 5.2 ArtiFex Medical GmbH Company Overview

      • 5.2.1 ArtiFex Medical GmbH Pipeline Products & Ongoing Clinical Trials Overview

    • 5.3 Axcelon Biopolymers Corp Company Overview

      • 5.3.1 Axcelon Biopolymers Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.4 CardioPolymers Inc Company Overview

      • 5.4.1 CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.5 Cardious Inc Company Overview

      • 5.5.1 Cardious Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.6 Centre Hospitalier Universitaire de Nice Company Overview

      • 5.6.1 Centre Hospitalier Universitaire de Nice Pipeline Products & Ongoing Clinical Trials Overview

    • 5.7 Coromedic Ltd. Company Overview

      • 5.7.1 Coromedic Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.8 Cytograft Tissue Engineering Inc (Inactive) Company Overview

      • 5.8.1 Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview

    • 5.9 Elana bv Company Overview

      • 5.9.1 Elana bv Pipeline Products & Ongoing Clinical Trials Overview

    • 5.10 enVVeno Medical Corp Company Overview

      • 5.10.1 enVVeno Medical Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.11 Graft-Loc Inc. Company Overview

      • 5.11.1 Graft-Loc Inc. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.12 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview

      • 5.12.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.13 iiTech BV Company Overview

      • 5.13.1 iiTech BV Pipeline Products & Ongoing Clinical Trials Overview

    • 5.14 McGill University Company Overview

      • 5.14.1 McGill University Pipeline Products & Ongoing Clinical Trials Overview

    • 5.15 Medical 21 Inc Company Overview

      • 5.15.1 Medical 21 Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.16 Myocardial Assist Systems and Technology LLC Company Overview

      • 5.16.1 Myocardial Assist Systems and Technology LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.17 Neograft Technologies Inc Company Overview

      • 5.17.1 Neograft Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.18 PetVivo Holdings Inc Company Overview

      • 5.18.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.19 Prekubator TTO Company Overview

      • 5.19.1 Prekubator TTO Pipeline Products & Ongoing Clinical Trials Overview

    • 5.20 RegenMedTX LLC Company Overview

      • 5.20.1 RegenMedTX LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.21 SeamVad Ltd. Company Overview

      • 5.21.1 SeamVad Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.22 Surg Solutions SL Company Overview

      • 5.22.1 Surg Solutions SL Pipeline Products & Ongoing Clinical Trials Overview

    • 5.23 Synovis Micro Companies Alliance Inc Company Overview

      • 5.23.1 Synovis Micro Companies Alliance Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.24 Thoratec LLC Company Overview

      • 5.24.1 Thoratec LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.25 Tissue Regeneration Technologies LLC Company Overview

      • 5.25.1 Tissue Regeneration Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.26 University College London Company Overview

      • 5.26.1 University College London Pipeline Products & Ongoing Clinical Trials Overview

    • 5.27 University of Arizona Company Overview

      • 5.27.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview

    • 5.28 University of California Davis Company Overview

      • 5.28.1 University of California Davis Pipeline Products & Ongoing Clinical Trials Overview

    • 5.29 University of California Los Angeles Company Overview

      • 5.29.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview

    • 5.30 Xeltis AG Company Overview

      • 5.30.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview

  • 6 Coronary Artery Bypass Graft Surgery- Recent Developments

    • 6.1 Jan 30, 2023: Medtronic appoints Michael Blackwell as India vice-president
    • 6.2 Jan 30, 2023: Medtronic India appoints Michael Blackwell as Vice President
    • 6.3 Jan 18, 2023: Sharecare launches virtual model of its medicare-reimbursable cardiac rehabilitation program, Ornish Lifestyle Medicine
    • 6.4 Jan 05, 2023: New study of self-forming magnetic anastomosis compared to stapler demonstrates improved anastomosis healing qualities in a pre-clinical study
    • 6.5 Dec 20, 2022: AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
    • 6.6 Dec 20, 2022: Icahn School of Medicine : Digital marker for coronary artery disease built by researchers at Mount Sinai
    • 6.7 Nov 23, 2022: Medtronic Reports Quarterly Earnings
    • 6.8 Nov 22, 2022: Medtronic reports second quarter fiscal 2023 financial results
    • 6.9 Nov 15, 2022: Medtronic Set to Announce Earnings on Tuesday
    • 6.10 Oct 17, 2022: LeMaitre Will Announce Third Quarter 2022 Earnings Results October 27, 2022
    • 6.11 Oct 12, 2022: Cardiovascular Systems to Host Earnings Conference Call on November 3, 2022
    • 6.12 Oct 11, 2022: AtriCure to Announce Third Quarter 2022 Financial Results
    • 6.13 Sep 07, 2022: Medtronic to appear at September investor conferences
    • 6.14 Sep 05, 2022: Sanofi announce Evolution of the Board of Directors
    • 6.15 Aug 31, 2022: LeMaitre to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
    • 6.16 Aug 25, 2022: Atrion Announces CFO Succession Plan
    • 6.17 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results
    • 6.18 Aug 23, 2022: Medtronic Announces Quarterly Earnings Results
    • 6.19 Aug 20, 2022: Herbert Smith Freehills advises Sanofi on €300 million equity investment in Innovent
    • 6.20 Aug 16, 2022: AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
    • 6.21 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule
    • 6.22 Aug 02, 2022: AtriCure Reports Second Quarter 2022 Financial Results
    • 6.23 Aug 01, 2022: Audrey Derveloy appointed President of Sanofi France
    • 6.24 Jul 28, 2022: Sanofi’s half-year financial report for 2022
    • 6.25 Jul 28, 2022: LeMaitre Q2 2022 Financial Results
    • 6.26 Jul 20, 2022: AtriCure to Participate at Upcoming Investor Conferences
    • 6.27 Jul 18, 2022: LeMaitre Will Announce Second Quarter 2022 Earnings Results July 28, 2022
    • 6.28 Jul 12, 2022: AtriCure to Announce Second Quarter 2022 Financial Results
    • 6.29 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director
    • 6.30 Jun 07, 2022: Cardiovascular Systems chief operating officer Rhonda Robb exits company
    • 6.31 Jun 01, 2022: AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
    • 6.32 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results
    • 6.33 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase
    • 6.34 May 03, 2022: Sanofi: Annual General Meeting of May 3, 2022
    • 6.35 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022
    • 6.36 Apr 28, 2022: LeMaitre Q1 2022 Financial Results
    • 6.37 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022
    • 6.38 Apr 15, 2022: LeMaitre Will Announce First Quarter 2022 Earnings Results April 28, 2022
    • 6.39 Apr 14, 2022: Leading Quantum Scientist Prineha Narang Appointed to Named Professorship at UCLA
    • 6.40 Apr 11, 2022: AtriCure to Announce First Quarter 2022 Financial Results
    • 6.41 Apr 06, 2022: Sanofi shutters Kadmon’s NY site and chops 25 staffers
    • 6.42 Feb 24, 2022: LeMaitre Q4 2021 Financial Results
    • 6.43 Feb 11, 2022: LeMaitre Will Announce Fourth Quarter 2021 Earnings Results February 24, 2022

  • 7 Appendix

    • 7.1 Methodology
    • 7.2 About GlobalData
    • 7.3 Contact Us

Table

Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development 10

Coronary Artery Bypass Graft Surgery – Pipeline Products by Territory 11

Coronary Artery Bypass Graft Surgery – Pipeline Products by Regulatory Path 12

Coronary Artery Bypass Graft Surgery – Pipeline Products by Estimated Approval Date 13

Coronary Artery Bypass Graft Surgery – Ongoing Clinical Trials 14

Coronary Artery Bypass Graft Surgery Companies – Pipeline Products by Stage of Development 15

Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development 17

AdvanSource Biomaterials Corporation Pipeline Products & Ongoing Clinical Trials Overview 18

CardioPass – Product Status 18

CardioPass – Product Description 18

ArtiFex Medical GmbH Pipeline Products & Ongoing Clinical Trials Overview 19

ArtiFex Vascular Graft – Product Status 19

ArtiFex Vascular Graft – Product Description 19

Axcelon Biopolymers Corp Pipeline Products & Ongoing Clinical Trials Overview 20

BNC – PVA Based Vascular Graft – Product Status 20

BNC – PVA Based Vascular Graft – Product Description 20

CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview 21

Plexisyl-AF – Product Status 21

Plexisyl-AF – Product Description 21

Cardious Inc Pipeline Products & Ongoing Clinical Trials Overview 22

AvA Aortic Valve Bypass Graft System – Product Status 22

AvA Aortic Valve Bypass Graft System – Product Description 22

Centre Hospitalier Universitaire de Nice Pipeline Products & Ongoing Clinical Trials Overview 23

Shark Anastomosis Connector – Product Status 23

Shark Anastomosis Connector – Product Description 23

Coromedic Ltd. Pipeline Products & Ongoing Clinical Trials Overview 24

Distal Anastomosis Device – Product Status 24

Distal Anastomosis Device – Product Description 24

Proximal Anastomosis Device – Product Status 25

Proximal Anastomosis Device – Product Description 25

Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 26

LifeLine TEBV – CABG – Product Status 26

LifeLine TEBV – CABG – Product Description 26

Elana bv Pipeline Products & Ongoing Clinical Trials Overview 27

ELANA CLIP 3.0 – Product Status 27

ELANA CLIP 3.0 – Product Description 27

enVVeno Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 28

CoreoGraft – Product Status 28

CoreoGraft – Product Description 28

enVVeno Medical Corp – Ongoing Clinical Trials Overview 29

CoreoGraft – First-in-human Trial Evaluating the Efficacy of CoreoGraft in the Coronary Artery Bypass Graft (CABG) Surgery 30

Graft-Loc Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

Graft-Loc Device – Product Status 31

Graft-Loc Device – Product Description 31

H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Vascular Stent – Product Status 32

Vascular Stent – Product Description 32

iiTech BV Pipeline Products & Ongoing Clinical Trials Overview 33

S² Distal Anastomotic System – Product Status 33

S² Distal Anastomotic System – Product Description 33

S2 Proximal Anastomotic System – Product Status 34

S2 Proximal Anastomotic System – Product Description 34

McGill University Pipeline Products & Ongoing Clinical Trials Overview 35

Transcatheter Aorta Pulmonary Shunt – Product Status 35

Transcatheter Aorta Pulmonary Shunt – Product Description 35

Medical 21 Inc Pipeline Products & Ongoing Clinical Trials Overview 36

Maverics Graft – Product Status 36

Maverics Graft – Product Description 36

Myocardial Assist Systems and Technology LLC Pipeline Products & Ongoing Clinical Trials Overview 37

Sutureless Anastomotic Graft Connection Device – Product Status 37

Sutureless Anastomotic Graft Connection Device – Product Description 37

Neograft Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 38

Neovaso – Product Status 38

Neovaso – Product Description 38

PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 39

Coronary Artery Bypass Graft – Product Status 39

Coronary Artery Bypass Graft – Product Description 39

Prekubator TTO Pipeline Products & Ongoing Clinical Trials Overview 40

Snapcon – Product Status 40

Snapcon – Product Description 40

RegenMedTX LLC Pipeline Products & Ongoing Clinical Trials Overview 41

Neo-Vessel Replacement – Coronary Artery Bypass – Product Status 41

Neo-Vessel Replacement – Coronary Artery Bypass – Product Description 41

SeamVad Ltd. Pipeline Products & Ongoing Clinical Trials Overview 42

MySide – Product Status 42

MySide – Product Description 42

Surg Solutions SL Pipeline Products & Ongoing Clinical Trials Overview 43

VessConnect – Product Status 43

VessConnect – Product Description 43

Synovis Micro Companies Alliance Inc Pipeline Products & Ongoing Clinical Trials Overview 44

Arterial Everter – Product Status 44

Arterial Everter – Product Description 44

Thoratec LLC Pipeline Products & Ongoing Clinical Trials Overview 45

Automated Anastomosis Device – Product Status 45

Automated Anastomosis Device – Product Description 45

Tissue Regeneration Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 46

Cardiogold – Product Status 46

Cardiogold – Product Description 46

University College London Pipeline Products & Ongoing Clinical Trials Overview 47

Small Diameter Conduit – Product Status 47

Small Diameter Conduit – Product Description 47

University of Arizona Pipeline Products & Ongoing Clinical Trials Overview 48

Vascular Anastomosis Device – Product Status 48

Vascular Anastomosis Device – Product Description 48

University of California Davis Pipeline Products & Ongoing Clinical Trials Overview 49

Vascular Anastomosis Device – Product Status 49

Vascular Anastomosis Device – Product Description 49

University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 50

Sutureless Anastomosis Device – Product Status 50

Sutureless Anastomosis Device – Product Description 50

Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 51

Xeltis Coronary Artery Bypass Graft – Product Status 51

Xeltis Coronary Artery Bypass Graft – Product Description 51

Xeltis AG – Ongoing Clinical Trials Overview 52

Xeltis Coronary Artery Bypass Graft – Prospective, Non-randomized, First in Human (FIH) Clinical Study to Assess the Feasibility of the Novel Xeltis Coronary Artery Bypass Graft (XABG) 53

Glossary 86

Figures

Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development 10

Coronary Artery Bypass Graft Surgery – Pipeline Products by Territory 11

Coronary Artery Bypass Graft Surgery – Pipeline Products by Regulatory Path 12

Coronary Artery Bypass Graft Surgery – Pipeline Products by Estimated Approval Date 13

Coronary Artery Bypass Graft Surgery – Ongoing Clinical Trials 14

Frequently asked questions

Coronary Artery Bypass Graft Surgery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Coronary Artery Bypass Graft Surgery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Coronary Artery Bypass Graft Surgery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Coronary Artery Bypass Graft Surgery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.